cabergoline has been researched along with Weight Gain in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Auriemma, RS; Colao, A; Graziadio, C; Pirchio, R; Pivonello, R | 1 |
Grattan, D; Manning, PJ; Manning, T; Merriman, T; Sutherland, W; Williams, S | 1 |
Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
Biondi, B; Briganti, F; Cappabianca, P; Colao, A; Faggiano, A; Lombardi, G; Pivonello, R; Sarno, AD; Somma, CD | 1 |
1 review(s) available for cabergoline and Weight Gain
Article | Year |
---|---|
Metabolic effects of prolactin.
Topics: Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Glucose; Humans; Hyperprolactinemia; Lipids; Male; Metabolic Syndrome; Obesity; Prolactin; Receptors, Dopamine; Receptors, Prolactin; Testosterone; Weight Gain | 2022 |
2 trial(s) available for cabergoline and Weight Gain
Article | Year |
---|---|
Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline.
Topics: Adult; Cabergoline; Diet, Reducing; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Secondary Prevention; Treatment Outcome; Weight Gain; Weight Loss; Young Adult | 2018 |
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Follow-Up Studies; Galactose; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Sex Characteristics; Sexual Dysfunction, Physiological; Treatment Outcome; Visual Fields; Weight Gain | 2003 |
1 other study(ies) available for cabergoline and Weight Gain
Article | Year |
---|---|
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |